Peptides researched for
Hypoactive sexual desire (HSDD)
Low sexual desire in women
1 peptide · 2 studies
What people research this for
Some women lose their interest in sex and find it distressing. They want to feel desire again. Bremelanotide, also known as PT-141, has been through large trials and has FDA approval for one specific group of women.
Researched for
- Low sexual desire in women
- Desire before menopause
What the studies say so far
The RECONNECT trials were late-stage studies of bremelanotide in women who had not reached menopause and whose low desire developed over time. Published papers report how it performed in different subgroups and what side effects came up. It is available by prescription only, and the approval covers that group and no one else.
Peptides studied
Each peptide below has been studied in this area. The label shows how far that research has gone.
PT-141
Tested in clinical trialsRandomized trial in people · 2 studies
Study note. RECONNECT phase 3 publications report efficacy subgroup and safety outcomes for bremelanotide in acquired generalized HSDD.
- Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide. (opens in a new tab)
Simon JA, Kingsberg SA, Portman D · Journal of women's health (2002) · 2022 · PubMed
- Safety Profile of Bremelanotide Across the Clinical Development Program. (opens in a new tab)
Clayton AH, Kingsberg SA, Portman D · Journal of women's health (2002) · 2022 · PubMed
- Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide. (opens in a new tab)
Look this up in the PeptIQ app
The app has the same research and sources, next to the tools you use to track your own protocol.
